The antimicrobial peptide LL37 and its truncated derivatives potentiates proinflammatory cytokine induction by lipoteichoic acid in whole blood

ANNA GUSTAFSSON1, STEFANIE SIGEL2 & LENNART LJUNGGREN1

1Department of Biomedical Laboratory Science, Malmö University, Malmö, Sweden, and 2Biochemical Pharmacology, University of Konstanz, Konstanz, Germany

Abstract
Interactions of bacterial and host products in activating the innate immune system is an important area to address. The role of lipoteichoic acid (LTA) in these interactions is particularly important because it is understudied in comparison to other factors. This study evaluated the effect of cationic peptides (CPs) on LTA-induced proinflammatory cytokine production in human whole blood and on purified leukocytes. Four different CPs of truncated derivatives from the known peptides LL37, BPI, and CP207 were used. Two of the CPs (IG33 and LL33), derivatives from LL37, potentiated S. aureus LTA induced TNF\(\alpha\), IL-6 and IL-1\(\beta\) production in whole blood. The release of TNF\(\alpha\) was increased 30-fold after 16 hours incubation. Intact LL37 also increased LTA-induced TNF\(\alpha\) and IL-1\(\beta\) in a time dependent manner. LTA in combination with either LL33 or IG23 demonstrated a synergistic enhanced TNF\(\alpha\) and IL-1\(\beta\) secretion on isolated leukocytes but not on purified monocytes. When complexed with IG23 and LL33, the electrophoretic mobility of LTA was altered in a non-denaturating gel electrophoresis. LTA was disaggregated and migrated more rapidly, suggesting an amphiphilic effect of CPs on LTA. In conclusion, LTA synergizes with LL37 and its truncated derivatives and this may lead to proinflammatory cytokine production and cause problems in sepsis therapy.

Key Words: Cationic peptides, ELISA, interleukin-1 beta, sepsis, tumor necrosis factor-alpha

Introduction
The best known pathogen-associated molecular patterns (PAMPs) responsible for an inflammatory response are lipopolysaccharide (LPS, endotoxin), lipoteichoic acid (LTA) and peptidoglycan [1]. LTA is a major cell wall component of Gram-positive bacteria and has an amphiphilic molecular structure, containing a substituted poly(glycerophosphate) backbone attached to a glycolipid. LTA is considered to be the counterpart of LPS derived from Gram-negative bacteria. Once LTA is recognized by toll-like receptor 2, downstream signals trigger the innate immune responses resulting in induction of cytokines such as interleukin-1\(\beta\) (IL-1\(\beta\)), interleukin-6 (IL-6) and tumor necrosis factor-\(\alpha\) (TNF\(\alpha\)) [2]. Low concentrations of these cytokines cause beneficial proinflammatory responses and fever, but an excessive response can lead to defect circulation, multi organ failure and death [3]. Antimicrobial peptides (AMPs) play a key role in the protection against PAMPs in almost all forms of multicellular hosts; they are cationic and their microbicidal action is initiated through interactions with the anionic bacterial surface [4]. Furthermore they are surface active agents which may bind to or penetrate through cellular membranes and induce lysis. AMPs exert not only antimicrobial activity but can also interact with free LPS and LTA [5]. There are many studies evaluating interactions between AMPs and LPS however, to date, there have been relatively few studies on AMPs interactions with LTA. However, AMPs neutralize the inflammatory effect of LTA, e.g. Scott et al. showed that CEME and CEME-related peptides inhibited LTA-induced production of TNF\(\alpha\) and IL-6 by RAW 264.7 cells and in human whole blood [6] and also that LL37 inhibited TNF\(\alpha\) production by LTA in RAW 264.7 cells [7]. Furthermore Kandler et al. [8] showed that LL37 inhibited the
production of IL-6, TNFα and IL-12 induced by LTA on dendritic cells. Nell et al. [9] also demonstrated that LL37 inhibited IL-8 production in whole blood stimulated with LTA.

It has also been shown that LTA synergizes with human proteins to stimulate cytokine secretion from human blood cells, for example LTA is markedly enhanced by hemoglobin [10,11] glycosphingolipids [12,13], or muramyl dipeptide [14].

We have previously shown that cationic peptides (CPs) derived from LL37, SC4 (BPI) and CP107 (CEME) block LPS induced proinflammatory cytokines in whole blood [15]. The CPs were all selected from promising LPS neutralization and binding experiments presented in the literature. Considering that Gram-positive bacteria account for up to 50% of severe sepsis or septic shock cases [16] we wished to analyse the effect of these CPs on whole blood responses to LTA. The hypothesis was that LTA activation in whole blood should be inhibited by CPs.

**Materials and methods**

Butanol-extracted, structurally intact LTA from Staphylococcus aureus (S. aureus) were used (a generous gift of Dr S. von Aulock). LTA were tested for endotoxin contamination in the limulus amoebocyte lysate (LAL) assay (Charles- River/Endosafe, Charleston, USA) and were found to contain less than 0.005 EU/ml. Polymyxin B (PMB) was obtained from Sigma (St. Louis, MO). The CPs were obtained from Innovagen AB (Lund, Sweden). Purity of 95% was determined by HPLC. KL12: NH₂-KLFFKRLHK WKKIC-COOH (derivative from SC4/BPI), KW27: NH₂-KWKKFIKLTSDLKKLVTTAKPLISSC -CCOH (CP207), IG23: NH₂-IKEFKRIVQRIKD FLRNLPRTC-COOH (LL37, peptide 13-35), LL33: NH₂-LLGDFFRKSKKIGKEFKRIVQR IKDRLNVLVC-COOH (LL37, peptide 1-32), LL37: NH₂-LLGDFFRKSKKIGKEFKRIVQRKDFL RNLVPRTES-COOH. The truncated peptides were terminated with cystein in the carboxy end in order to specifically immobilize them onto a solid matrix in an equal manner and initially to evaluate the interaction with LPS [15].

**Whole blood incubations**

Heparinized blood was obtained from healthy donors. Stock solutions of the different CPs were prepared in LAL water. Each CP (50 μl) was mixed with 50 μl LTA (100 μg/ml) and diluted with 1 ml 0.9% physiological saline prior to addition of 100 μl blood. The mixtures were incubated for 1, 3, 6, 12, 16 or 24 h respectively at 37°C and 5% CO₂. The final concentration was: LTA 4 μg/ml and CPs 4 or 20 μM. After incubation, samples were resuspended and spun down (2 min at 1000 g) and supernatants were analyzed immediately or stored at −80°C until cytokine measurement.

**Isolation of human leukocytes**

Mononuclear cell or polymorphonuclear (PMN) cell fractions of human leukocytes were isolated by centrifugation with Polymorphprep (Nycomed Pharma AS, Majorstua, Norway) according to the manufacturer’s instructions. After centrifugation, two leukocyte bands (mononuclear cells in the top band and PMNs in the lower one) were obtained which were harvested, washed, and centrifuged (500 g, 10 min). The autologous plasma on top of the mononuclear cells was also collected. To obtain a mix of leukocytes, both mononuclear cells and PMNs were resuspended in the autologous plasma. For isolation of monocytes, mononuclear cells were plated in 96-well tissue culture plates at 10⁶/ml (100 μl/well) and after 2 h at 37°C, 5% CO₂ the lymphocytes were washed away with 0.9% saline and to the adherent monocytes 0.9% saline containing 5% autologous plasma was added. PMNs were plated in 96-well tissue culture plates at 2.5 × 10⁶/ml (100 μl/well) suspended in 0.9% saline containing 5% autologous plasma.

**Stimulation of human leukocytes**

Stock solution of IG23 were prepared in LAL water and mixed with LTA and hemoglobin (Hb). Each sample of 100 μl was diluted with 1 ml 0.9% saline and incubated with 100 μl isolated leukocytes at 1, 3, 6, 12, or 24 h respectively at 37 °C and 5% CO₂ in a 1.5 ml polypropylene reaction vial. The final concentration was: LTA 4 μg/ml, IG23 20 μM and Hb 50 μg/ml. Release of TNFα was quantified after the indicated hours.

**Stimulation of human monocytes and PMNs**

Isolated monocytes (10⁶/ml) or PMNs (2.5 × 10⁶/ ml) in 0.9% saline containing 5% autologous plasma were treated with LTA (4 μg/ml) and IG23, LL33 or PMB (20 μM) for 3 and 9 h respectively. Aliquots of the culture medium were assayed immediately for IL-1β and TNFα release.

**Cytokine ELISA**

IL-1β, IL-6 and TNFα were quantified using ELISA Set (BD OptEIA by BD Opt EIA Biosciences, San Diego USA) according to the manufacturer’s instructions. Assays were carried out in flat-bottom 96-well immunoplates (MaxiSorp, nunc, Wiesbaden Germany).

**Cell viability with Alamar Blue**

The impact on cell viability of the CPs and LTA was evaluated using the Alamar Blue assay [17]. Experiments were carried out in 96-well black plates with
a clear bottom (Costar, Corning Inc., Corning, NY, USA) to minimize fluorescence interference between wells. The CPs (20 μM) with or without LTA (4 μg/ml) were incubated with either whole blood (1:10 in 0.9% saline) or leukocytes (1:10 in 0.9% saline, isolated from human whole blood, see isolation of human leukocytes), or monocytes (isolated from human blood, 10^6/ml in 0.9% saline with 5% autologous plasma) or PMNs (isolated from human blood, 2.5 × 10^6/ml in 0.9% saline with 5% autologous plasma) 20 h at 37°C and 5% CO₂. The Alamar Blue solution (1/10) (Biotium, Inc, CA, USA) was added to each well and cells incubated for 4 h. The fluorescence intensity was measured on a Spectra Max Gemini XS microplate spectrophotometer (Molecular Device, Sunnyvale, CA, USA) with an excitation wavelength of 545 nm and an emission wavelength of 590 nm. Whole blood samples were centrifuged (300 g for 2 min) before measurement. The fluorescence values were normalized by the controls (untreated cells) and expressed as percent viability.

**Hemolytic activity of CPs**

Human erythrocytes were obtained from freshly collected whole blood, centrifuged at 800 g for 10 min, and washed with 20 mM Hepes buffer with 150 mM NaCl pH 7.4. The assay was performed in Hepes buffer with 150 mM NaCl by incubating 2.5% (vol/vol) erythrocyte suspensions with various amounts of CPs (0–200 μM) for 30 min at 37°C. After centrifugation at 800 g for 10 min, the supernatant was carefully removed, and the release of hemoglobin measured at 577 nm. The percentage of hemolysis was determined as (A_peptide − A_blank)/(A_total − A_blank) × 100, where A_blank and A_total correspond respectively to the hemolysis in the absence of the CPs and to 100% hemolysis as obtained by addition of 2% Triton X-100.

**Non-denaturing PAGE of LTA/CP mixtures and staining procedure**

LTA (10 μg) were incubated in the absence or presence of 1 μg or 10 μg IG23, LL33 or PMB, respectively, for 30 min at 37 °C. As controls 10 μg IG23, LL33 or PMB without LTA was incubated. Samples were resolved in tris-glycine buffer (25 mM Tris, pH 8.3, 192 mM glycine) on a 12 % native polyacrylamide gel at 200V. Following electrophoresis, gels were stained using Bio-Rad Silver Stain kit (Bio-Rad, Munich, Germany) according to the manufacturer’s instructions.

**Statistical analysis**

All experiments were performed in duplicate a minimum of three times. Values are presented as means ± standard deviation (SD). In case of two groups, data was analysed with paired t-test. Differences were considered significant when p < 0.05 (*p < 0.01; **p < 0.001; ***p < 0.001).

**Results**

**Cytokine release after whole blood incubations**

Experiments with LTA incubations in whole blood showed that CPs enhanced LTA-induced IL-1β production (significant for KL12, IG23 and LL33) and more over IG23 and LL33 also significantly enhanced LTA induced production of both TNFα and IL-6 as depicted in Figure 1. Pure CPs (20 μM) did not induce any detectable cytokine production. KW27 had no effect on LTA-induced cytokine production in whole blood. PMB significantly enhanced IL-1β production but had no effect on IL-6 or TNFα. Since IG23 and LL33 had the strongest effect on LTA-induced cytokine secretion a time study with these CPs was made, in this experiment intact LL37 was included. As shown in Figure 2, IG23, LL33 and LL37 all potentiated LTA-induced IL-1β secretion and TNFα secretion in a time-dependent manner. Regarding TNFα secretion, it looked like the CPs induced a biphasic pattern as compared to LTA only. There was a very big biological variation in TNFα induction among the blood donors tested. This variation can be seen by comparing Figure 1 and 2. In Figure 1 (n = 9) TNFα production was increased 30-fold after 16 h while Figure 2B (n = 5) shows that TNFα production was increased 3-fold after 12 h. A lower concentration of the CPs was also tested; LL33 showed the same enhancement of LTA-induced cytokine production at 4 μM while IG23 of 4 μM showed no difference compared to LTA-treated cells as depicted in Figure 2C. To ensure that heparin did
not interfere with the signalling, EDTA blood and citrate were also tested. Those experiments showed the same pattern as heparinized blood although not resulting in such high cytokine levels (result not shown).

**Stimulation of PMNs and monocytes**

In order to complement the whole blood assay, we looked at purified components. No cytokine release was observed upon stimulation of PMNs with either LTA or in combination with the CPs, IG23 or LL33. The experiments on human monocytes showed that LL33 significantly inhibited LTA-induced IL-1β and TNFα secretion after 3 and 9 h as depicted in Figure 3. IG23 significantly inhibited TNFα secretion but not IL-1β secretion. PMB had no effect on LTA-induced TNFα production but a significantly inhibited LTA-induced IL-1β secretion was observed.

**Hemolysis**

Since Hb has been shown to stimulate LTA the hemolytic effects of the CPs were analysed. KW27, LL33 and IG23 induced a concentration dependent hemolysis (Figure 4). KL12 and PMB were considered to be non hemolytic in the concentrations tested. In order to determine whether hemolysis played a role in CPs potentiating of LTA-induced cytokine secretion leukocytes (monocytes, lymphocytes, granulocytes and thrombocytes) without red blood cells were incubated with IG23, LTA and Hb. As shown in Figure 5, Hb itself enhanced LTA-induced TNFα secretion as previ-
Interestingly, also IG23 itself enhanced LTA-induced TNFα secretion. IG23 and Hb together gave an even stronger enhancement of LTA-induced TNFα secretion in human leukocytes.

Cell viability

Peptide concentrations of 20 μM did not affect the viability of the monocytes, PMNs, leukocytes (1:10 in saline), or in whole blood (1:10 in saline) after 24 h incubation with or without LTA (4 μg/ml). Considering that KW27 and LL33 are hemolytic in the concentration tested (see Figure 4), hemoglobin interfered with the fluorescence measurements in the Alamar Blue assay in whole blood and gave a false low fluorescence. Leukocytes challenged with LL33 or KW27 (20 μM) together with Hb (1 mg/ml) showed no reduction of fluorescence compared to leukocytes treated with only Hb (1 mg/ml).

Nondenaturating PAGE of LTA/CP mixtures

To determine whether the synergistic effect of the LTA-CPs mixtures could be due to physical interactions between the two molecules a non-denaturing gel electrophoresis was performed followed by silver staining. Although LTA migrates on a SDS-PAGE gel at ~8–10 kDa, it migrates much slower and in a diffuse manner on a nondenaturating gel (see Figure 6). This migration pattern may be explained by the ability of LTA to form micelles in aqueous solution [18]. Figure 6 shows that when incubated with LL33 or IG23 at weight ratio 1:1, LTA disaggregates and migrates faster and more diffusely. PMB had no effect on LTA migration.
Discussion

The roles of CPs as therapeutic agents are of great importance at the present moment as the research on new antibiotic drugs have limited interest within the pharmaceutical industry. The use of CPs for the treatment of Gram-positive sepsis would be beneficial as previously demonstrated for Gram-negative sepsis. The general hypothesis is that CPs neutralize the inflammatory effects of LTA. This study showed the opposite since costimulation with some CPs and LTA from S. aureus, the most prevalent Gram-positive pathogen, potentiate the induced production of the pro-inflammatory cytokines IL-1β, IL-6 and TNFα in whole blood. In other words, CPs may contribute to the inflammation caused by LTA rather than inhibit it. In particular, IG23 and LL33, truncated derivatives from the cathelicidin hCAP18, induced high levels of TNFα in whole blood and leukocytes. hCAP18 is present in human PMNs, and is expressed throughout epithelia in many organs and can be cleaved extracellular to generate the AMP LL37 [19]. It has been demonstrated that some CPs inhibit cytokine production by monocytes or in whole blood stimulated with commercial available LTA from S. aureus. For example, Scott et al. [6] showed that CP207 which differs from KW27 only at the C-terminal end, where KW27 has an additional cystein residue, inhibited LTA-stimulated (S. aureus, B. subtilius and S. pyrogenes from Sigma) production of TNFα and IL-6 induction by RAW 264.7 cells. In the present study KW27 had no effect on LTA-induced cytokine production in whole blood, the effect on isolated monocytes was not tested. KL12 has previously been shown to have good activity against gram-positive bacteria [20] and in the present study it potentiated LTA-induced IL-1β production. Kandler et al. [8] showed that LL37 inhibited the production of IL-6, TNFα and IL-12 induced by commercial LTA on dendritic cells. In the present study IG23 and LL33 inhibited LTA-induced TNFα production on monocytes but not in whole blood or the leukocyte mix. These results indicate that a whole blood system, i.e. interactions between the leukocytes, rather than isolated monocytes is essential for the enhanced LTA-induced cytokine secretion by LL37.

It has been demonstrated that commercial preparations of LTA contains significant amounts of endotoxin [21,22], which contributes to the observed biological activities such as induction of inflammatory mediators in various types of cells. Chromatographic purification of commercially S. aureus LTA eliminates its immunostimulatory potential [22–24]. Morath et al. [23] demonstrated that commercial LTA contained considerable contamination by non-LTA, non-LPS immunostimulatory contamination in HIC fractions not typical for either LTA or LPS. There are also doubts about the quality of the commercial preparations of LTA. Morath et al. [25] revealed that alanine substituents are lost during phenol extraction. In the present study LTA were purified using butanol extraction to preserve D-alanine constituents, which are important to maintain the LTA proinflammatory activity [25].

Deininger et al. [26] showed that adhesion of LTA to a polystyrene surface drastically increased its immunostimulatory potency in human whole blood in comparison to soluble LTA. The release of the proinflammatory cytokines IL-1β, TNFα and IL-6 and the chemokines IL-8 and G-CSF was increased 2- to 10-fold, but IL-10 release was unaltered. These findings indicated that LTA is only recognized by immune cells when it is presented on a surface. They also described that both LTA adhering to a surface and LTA covalently coupled on to a surface are able to induce cytokine release [26]. Draining et al. [27] investigated whether LTA monomers in solution can activate monocytes. They incubated monocytes in different vials, which did not allow LTA binding, as well as various beads binding LTA. Their results showed that when no binding of LTA to surfaces was possible, blood monocytes were not able to react to LTA.

It has previously been shown that stimulation of human monocytes by LTA is markedly enhanced by Hb [10,11]. Their hypothesis is that LTA forms a complex with Hb in a way that facilitates the presentation of LTA to the macrophage Toll-like receptors. In the present study, hemolysis is likely to contribute to the effect in whole blood considering the hemolytic effect of LL37 and IG23. However, Figure 5 shows that stimulation of leukocytes by LTA is enhanced by IG23 both with and without Hb. Moreover it is well known that the hemolytic effect of cationic peptides is drastically reduced in the presence of plasma [28,29]. The increased reactivity of LTA, when complexed with IG23 and LL33 and the altered electrophoretic mobility of LTA (Figure 6) may be explained by an amphipilic effect of CPs on LTA, making LTA more attractive for activation of human leukocytes. The interaction of LTA with Hb and glycosphingolipids has also been shown to change the migration of LTA in a nondenaturation gel [10,13].

This study has demonstrated that CPs, which binds LPS with high affinity [15], can interact synergistically

![Image](image_url)
with LTA and potentiate the induced cytokine production in whole blood, in a time- and concentration-dependent manner. The mechanism behind this must be evaluated further but nevertheless, some CPs can perhaps cause problems in treatment of Gram-positive sepsis. Although LTA is integrated in the cell wall of Gram-positive bacteria it can be released when bacteria are killed by either the host immune system or antibiotic treatment [16]. The interactions between free LTA and some CPs may activate immune cells and lead to induction of cytokine production rather than inhibition. The derivatives in this study were terminated with cysteine. It is well known that cystein residues may lead to a formation of disulfide bonds that in this case could alter the interaction affinity for LTA. However, in the present study regarding the potentiation of proinflammatory cytokine release similar effects have been observed for LL37 without the presence of cysteine. It would be of great interest to evaluate neutralization of LTA using these CPs when immobilized onto solid phases.

Acknowledgements

We thank Fatima Barakat for excellent technical assistance.

Declaration of interest: The authors declare no competing financial interests.

References